局限性前列腺癌立体定向体部放疗后的勃起功能
研究纳入2008至2013年单中心373例接受SBRT的局限性前列腺癌患者,用EPIC-26前瞻性采集生活质量数据。基线有功能勃起者24个月和60个月分别有57%和45%保留功能,SBRT后勃起率与其他放疗技术模型预测值无统计学差异。作者认为预后模型可用于咨询。
要点
- 基线有功能勃起者SBRT后24个月57%、60个月45%保留功能。
- 24个月模型含基线性HRQoL(aOR 1.55/10分)与年龄(aOR 0.66/10年)。
- SBRT后勃起率与EBRT或近距离放疗模型预测值无统计学差异。
核心结论
- SBRT后中长期勃起功能结果令人鼓舞,且与其他放疗技术无显著差异。
- 临床医生可用该预后模型就SBRT后预期勃起功能进行咨询。
研究设计与样本
- 2008至2013年单中心373例连续性局限性前列腺癌患者接受SBRT,作为前瞻性临床试验或前瞻性登记的一部分。
- 采用EPIC-26前瞻性纵向采集患者报告的健康相关生活质量数据,功能勃起严格定义为「坚硬足以性交」。
- 同时采集详细合并症数据,用逻辑回归模型预测24个月和60个月功能勃起率。
- 将SBRT后观察到的勃起率与其他放疗(EBRT和近距离放疗)前瞻性验证模型的预测率进行比较。
主要发现
- 中位随访56个月(四分位距37-73),2年应答率84%。
- 基线有功能勃起者中,24个月和60个月分别有57%和45%保留功能。
- 24个月勃起功能多变量分析中,基线性HRQoL较高(每10分aOR 1.55,95%CI 1.37-1.74;P<0.001)与年龄较大(每10年aOR 0.66,95%CI 0.43-1.00;P=0.05)为显著变量。
- 60个月时基线HRQoL和年龄仍与勃起功能相关,体质指数(aOR 0.45,95%CI 0.26-0.78;P<0.001)也相关。
- 24个月和60个月模型区分度极好(c-index分别为0.81和0.84)。
关键数值与推荐
- 功能勃起严格定义为根据EPIC-26「坚硬足以性交」。
- 24个月模型:基线性HRQoL每增加10分aOR 1.55(95%CI 1.37-1.74;P<0.001),年龄每增加10年aOR 0.66(95%CI 0.43-1.00;P=0.05)。
- 60个月模型:体质指数aOR 0.45(95%CI 0.26-0.78;P<0.001),基线HRQoL和年龄仍相关(原文未报告具体数值)。
- 模型区分度:24个月c-index 0.81,60个月c-index 0.84。
临床怎么用
- 作者认为临床医生可用该预后模型就SBRT后预期勃起功能向患者提供咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To elucidate the functional erection rate after prostate stereotactic body radiotherapy (SBRT) and to develop a comprehensive prognostic model of outcomes after treatment. PATIENTS AND METHODS: Between 2008 and 2013, 373 consecutive men with localized prostate cancer were treated with SBRT at a single academic institution as part of a prospective clinical trial or prospective registry. Prospective longitudinal patient-reported health-related quality of life (HRQoL) data was collected using the Expanded Prostate Cancer Index Composite (EPIC)-26 instrument. Functional erections were strictly defined as 'firm enough for intercourse' according to EPIC-26. Detailed comorbidity data were also collected. Logistic regression models were used to predict 24- and 60-month functional erection rates. Observed erection rates after SBRT were compared with those after other radiation therapies (external beam radiation therapy [EBRT] and brachytherapy) using prospectively validated models. RESULTS: The median (interquartile range) follow-up was 56 (37-73) months and the response rate at 2 years was 84%. For those with functional erections at baseline, 57% and 45% retained function at 24 and 60 months, respectively. On multivariable analysis for 24-month erectile function, significant variables included higher baseline sexual HRQoL (adjusted odds ratio [aOR] 1.55 per 10 points, 95% confidence interval [CI] 1.37-1.74; P < 0.001) and older age (aOR 0.66 per 10 years, 95% CI 0.43-1.00; P = 0.05). At 60 months, baseline HRQoL and age remained associated with erectile function, along with body mass index (aOR 0.45, 95% CI 0.26-0.78; P < 0.001). The 24- and 60-month models had excellent discrimination (c-index 0.81 and 0.84, respectively). Erection rates after SBRT were not statistically different from model-predicted rates after EBRT or brachytherapy for the whole cohort and the cohort with baseline erectile function. CONCLUSIONS: Intermediate- to long-term post-SBRT erectile function results are promising and not significantly different from other radiotherapy techniques. Clinicians can use our prognostic model to counsel patients regarding expected erectile function after SBRT.
引用
- Dess RT, Hartman HE, Aghdam N, et al. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2017. PMID: 28710895. doi:10.1111/bju.13962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。